var data={"title":"Keratoacanthoma: Management and prognosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Keratoacanthoma: Management and prognosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Jerry D Brewer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/contributors\" class=\"contributor contributor_credentials\">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H771357\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Keratoacanthoma (KA) is a cutaneous squamoproliferative tumor that usually presents as a 1 to 2 cm dome-shaped or crateriform nodule with central hyperkeratosis (<a href=\"image.htm?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368\" class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \">picture 1A-E</a>). A common and distinctive feature of KA is a clinical course characterized by phases of rapid growth, lesion stability, and spontaneous involution.</p><p>The approach to the management of KA is debatable since lesions can resolve without treatment. However, the well-accepted difficulty in distinguishing KA from cutaneous squamous cell carcinoma, a common tumor associated with a risk for metastasis, leads many clinicians (including ourselves) to recommend treatment of these lesions.</p><p>The treatment and prognosis of KA will be discussed here. The epidemiology, risk factors, and diagnosis of KA are reviewed separately. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H770530\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A longstanding debate over the classification of KA as a benign, spontaneously resolving tumor versus a variant of cutaneous squamous cell carcinoma with a rare potential for metastasis has contributed to a lack of definitive guidelines on the treatment of these lesions. Although most authors, including ourselves, advocate for treatment of KA [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/1-7\" class=\"abstract_t\">1-7</a>], observation until spontaneous resolution has also been used for management of these lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/4,8\" class=\"abstract_t\">4,8</a>]. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H1923197\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Relationship with squamous cell carcinoma'</a>.)</p><p>We opt to treat KA based upon the following considerations [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No clinical or pathologic features can reliably differentiate KA and cutaneous squamous cell carcinoma </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment accelerates lesion resolution</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment is usually straight forward and efficient, with relatively minor risk</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early treatment may improve cosmetic outcomes by limiting damage to the skin and underlying structures, such as the nose, eyelids, or lips </p><p/><p>Surgical excision is the first-line treatment for patients with the most common clinical presentation of KA, a solitary lesion. Other therapeutic options for solitary KA include electrodesiccation and curettage (ED&amp;C), intralesional injections, radiation, and topical therapy. </p><p>We defer therapeutic intervention and proceed with observation only in patients who refuse to proceed with treatment. (See <a href=\"#H770593\" class=\"local\">'Deferring therapy'</a> below.)</p><p>The management of patients with numerous KAs or very large KAs is more challenging than the treatment of solitary KA since the methods typically used to treat individual lesions are often impractical in these settings. Systemic pharmacologic therapy is an additional treatment option for patients with large or numerous KAs. Oral retinoids, such as <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> and <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, are the systemic agents most commonly prescribed for this indication. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H15906018\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Clinical variants'</a> and <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H2295938\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Multiple keratoacanthomas'</a>.)</p><p class=\"headingAnchor\" id=\"H770537\"><span class=\"h1\">SOLITARY KERATOACANTHOMA</span></p><p class=\"headingAnchor\" id=\"H380984\"><span class=\"h2\">First-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conventional surgical excision is the treatment of choice for solitary KA since it allows for both the assessment of histopathologic features to aid in diagnosis and pathologic confirmation of the removal of the tumor. Mohs surgery, a more complex and more expensive method of surgical excision, is usually reserved for patients in whom a tissue-sparing procedure is desired. In a single institution, retrospective study, both surgical excision and Mohs surgery were associated with a recurrence rate of &lt;1 percent [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=mohs-surgery\" class=\"medical medical_review\">&quot;Mohs surgery&quot;</a> and <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H772735\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H770544\"><span class=\"h3\">Conventional surgical excision</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the efficacy of conventional surgical excision for the treatment of KA has not been formally studied, this procedure is considered a first-line therapy for KA due to the fact that it is simple, well tolerated, and as noted above, provides histopathologic confirmation of tumor removal [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/2,7,9,10\" class=\"abstract_t\">2,7,9,10</a>].</p><p>The technique utilized to perform surgical excision is important to ensure adequate treatment. The excision should include a periphery of normal skin and should extend into the subcutaneous fat. Due to the well-accepted difficulty in distinguishing KA from cutaneous squamous cell carcinoma, we typically excise these lesions with the recommended surgical margins for squamous cell carcinoma (at least 4 mm) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H1923197\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Relationship with squamous cell carcinoma'</a> and <a href=\"topic.htm?path=treatment-and-prognosis-of-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">&quot;Treatment and prognosis of cutaneous squamous cell carcinoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H770551\"><span class=\"h3\">Mohs surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mohs surgery is a tissue-sparing surgical technique that also allows for the intraoperative assessment of 100 percent of the tissue margins, unlike conventional surgical excision, in which only representative sections of the tumor margin are examined [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/11\" class=\"abstract_t\">11</a>]. Mohs surgery requires greater time to perform than conventional surgical excision, and is a more costly and less widely available procedure. (See <a href=\"topic.htm?path=mohs-surgery\" class=\"medical medical_review\">&quot;Mohs surgery&quot;</a>.)</p><p>Cure rates for Mohs surgery for cutaneous squamous cell carcinoma are high, but data on the efficacy of Mohs surgery for KA are limited. In a large series of 95 patients with 119 KAs treated with Mohs surgery, one recurrence (0.8 percent) occurred three months after the initial treatment; a similar recurrence rate (0.9 percent) was observed among 100 patients with 112 KAs treated with conventional surgical excision [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Mohs surgery, when available, is the preferred treatment for KAs in areas such as the central face, ear, nose, and periocular and perioral skin since tissue sparing is desired in these sites. Mohs surgery may also be used for lesions greater than 2 cm in diameter (giant KA) since it allows for confirmation of tumor removal prior to wound closure and may minimize the size of the surgical defect [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/10\" class=\"abstract_t\">10</a>]. Intralesional pharmacologic therapy is an additional treatment option for such lesions. (See <a href=\"#H770579\" class=\"local\">'Intralesional therapy'</a> below.) </p><p class=\"headingAnchor\" id=\"H770565\"><span class=\"h2\">Alternative therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Examples of other therapies that have been used for the management of KA include electrodesiccation and curettage (ED&amp;C), intralesional pharmacologic therapy, ionizing radiation, and topical agents. Compared with surgical excision, the major disadvantage of these alternative procedures is the lack of histopathologic confirmation of the removal of the tumor. ED&amp;C is the most commonly used alternative therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H380965\"><span class=\"h3\">Electrodesiccation and curettage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ED&amp;C is a quick surgical procedure that is often used to treat KA after a shave biopsy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. The procedure involves three cycles in which curettage is followed by electrodesiccation of the lesion site. Only a few minutes are required to administer this therapy.</p><p>Data on the efficacy of ED&amp;C are limited. In a retrospective study of 111 KAs followed for 3 to 26 months, recurrence was detected in four lesions (4 percent) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/12\" class=\"abstract_t\">12</a>]. An overall recurrence rate of 8 percent was documented in a separate retrospective study in which 75 out of 78 patients received this treatment [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Although ED&amp;C is well tolerated, the round, hypopigmented scar that is typically left after healing makes this a less favorable option for some patients. The potential for this result is of particular concern when a KA is located in a cosmetically sensitive area. </p><p class=\"headingAnchor\" id=\"H770579\"><span class=\"h3\">Intralesional therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intralesional therapy is infrequently utilized for the treatment of KA. Data on the efficacy of these interventions are limited to reports of small numbers of patients, some of whom did not have pretreatment biopsies. Most of the reported cases involve the use of 5-fluorouracil (5-FU) or <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/13-15\" class=\"abstract_t\">13-15</a>]. Compared with 5-FU, intralesional methotrexate is a less expensive therapy.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>5-fluorouracil </strong>&ndash; The efficacy of 5-FU is supported by case reports and case series [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/16\" class=\"abstract_t\">16</a>]. The largest series, which consisted of 41 lesions, found a complete response rate of 98 percent [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/17\" class=\"abstract_t\">17</a>]. Intralesional 5-FU is typically administered undiluted in a concentration of 50 <span class=\"nowrap\">mg/mL</span> on a weekly basis for three to eight treatment sessions. The doses used for injection have varied widely; a dose of 40 to 75 mg per lesion was utilized in the largest series. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a><strong> </strong>&ndash; Resolution of KA after treatment with intralesional methotrexate has been reported in case reports and case series [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/14,16\" class=\"abstract_t\">14,16</a>]. In a series of nine patients with KA [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/15\" class=\"abstract_t\">15</a>], all lesions completely resolved, and in another series, complete responses occurred in 15 out of 18 patients (83 percent) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/14\" class=\"abstract_t\">14</a>]. In addition, intralesional methotrexate administered prior to surgical excision reduced lesion size in a randomized trial of 25 patients [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"bulletIndent1\">A standard dose for the treatment of KA is the injection of 1 mL of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> in a concentration of 12.5 or 25 <span class=\"nowrap\">mg/mL</span>. Injection is performed every two to three weeks for one to four treatment sessions. One or two treatments are usually sufficient for resolution. </p><p/><p>Data on the use of <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a> [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/19-22\" class=\"abstract_t\">19-22</a>] and interferon alfa-2a and alfa-2b [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/23,24\" class=\"abstract_t\">23,24</a>] are limited to case reports and case series with fewer than 10 patients [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/16\" class=\"abstract_t\">16</a>]. These agents also appear to be effective.</p><p>A common technique used to perform intralesional injection of a KA is the delivery of a total of five injections per lesion: a single injection into the center and one injection into each quadrant. The goal is to blanch the entire rim of the lesion [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Due to discomfort associated with the injection of 5-FU and <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, local anesthesia is frequently given prior to these injections. In contrast, anesthesia is not usually necessary for the administration of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> and interferon [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/16\" class=\"abstract_t\">16</a>]. In all cases, surgical excision with histopathologic evaluation is recommended if lesions fail to respond as expected to intralesional therapy. </p><p>The potential adverse effects common to these treatments include local pain, erythema, necrosis, ulceration, and crusting. The possibility that side effects associated with the systemic administration of these agents may occur must also be considered [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/16\" class=\"abstract_t\">16</a>]. Pancytopenia has occurred in two hemodialysis-dependent patients with renal failure after treatment with 25 mg of intralesional MTX [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/25,26\" class=\"abstract_t\">25,26</a>]. Thus, some authors have suggested obtaining a complete blood count before treatment and one week after injection of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H1564847\"><span class=\"h3\">Radiation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the efficacy of radiation therapy for KA is supported by case series and case reports [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/27-31\" class=\"abstract_t\">27-31</a>], this treatment is infrequently employed due to the multiple visits required and the potential long term consequences of radiation therapy. Radiation therapy is usually reserved for older adult patients for whom surgical treatment is not an option. (See <a href=\"topic.htm?path=treatment-of-basal-cell-carcinomas-at-high-risk-for-recurrence#H12329859\" class=\"medical medical_review\">&quot;Treatment of basal cell carcinomas at high risk for recurrence&quot;, section on 'Long-term complications'</a>.)</p><p>Guidelines for the administration of radiation therapy for KA have not been established. Of note, radiation therapy was associated with the induction of numerous new lesions in a patient with multiple self-healing squamous epithelioma (Ferguson-Smith disease), a genetic disorder characterized by the development of multiple KAs [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H2295938\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Multiple keratoacanthomas'</a>.)</p><p class=\"headingAnchor\" id=\"H210572\"><span class=\"h3\">Topical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resolution of KA following topical application of 5-FU has been documented in case reports and case series [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/33\" class=\"abstract_t\">33</a>]. A 5% formulation of 5-FU is typically applied daily, and resolution usually occurs within eight weeks [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The application of <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a> 5% cream has also been associated with lesion resolution within 4 to 11 weeks in case reports [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/36\" class=\"abstract_t\">36</a>]. Treatment is usually applied three to four times per week. Significant local inflammation commonly occurs during topical therapy.</p><p class=\"headingAnchor\" id=\"H770586\"><span class=\"h3\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other therapies that have been reported to be effective in small numbers of patients with KA include treatment with curettage alone, cryotherapy, an argon laser [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/37\" class=\"abstract_t\">37</a>], an Er:YAG laser in combination with topical 5-FU [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/38\" class=\"abstract_t\">38</a>], and photodynamic therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/39\" class=\"abstract_t\">39</a>]. Of note KA has been reported to occur as a consequence of trauma related to treatment with a fractional laser [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/40\" class=\"abstract_t\">40</a>], a CO<sub>2</sub> laser [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/41\" class=\"abstract_t\">41</a>], and cryotherapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/42,43\" class=\"abstract_t\">42,43</a>]. Worsening of a KA lesion has also been documented after photodynamic therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H770593\"><span class=\"h2\">Deferring therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the possibility for spontaneous resolution of solitary KA, occasional patients elect to defer therapy. When this approach is taken, close patient follow-up is recommended. Several guidelines have been proposed for the management of these patients [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/8\" class=\"abstract_t\">8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Follow-up from presentation through resolution should be performed by a single clinician experienced in the natural history of these lesions</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The course of the lesion should be documented with photographs every two to three weeks until lesion resolution</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patients must be informed that resolution may take six months or longer</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients should be informed of the option for surgical excision and other treatments</p><p/><p>We also inform patients who are considering deferring therapy of the possibility of aggressive lesion behavior and the chance for misdiagnosis of squamous cell carcinoma as KA. If, during the course of observation, the lesion develops an atypical appearance, growth fails to cease, or the tumor fails to regress as expected, surgical excision with histopathologic examination of the lesion is indicated [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H2295744\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Solitary keratoacanthoma'</a>.)</p><p class=\"headingAnchor\" id=\"H770600\"><span class=\"h1\">SPECIAL CASES</span></p><p class=\"headingAnchor\" id=\"H207224\"><span class=\"h2\">Multiple and large keratoacanthomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of numerous KAs, such as those seen in the rare multiple KA syndromes, and the extremely large lesions that characterize keratoacanthoma centrifugum marginatum presents unique challenges. Although surgical intervention and the other local therapies described above remain options for treatment, such therapies are usually impractical in patients with hundreds or thousands of lesions. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H2295938\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Multiple keratoacanthomas'</a> and <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H15906018\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Clinical variants'</a>.)</p><p>Systemic agents are an additional option for these patients. Multiple case reports have documented the efficacy of oral retinoids in patients with multiple self-healing squamous epithelioma (MSSE) or generalized eruptive keratoacanthoma of Grzybowski [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/32,45-57\" class=\"abstract_t\">32,45-57</a>]. <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a> (25 to 60 mg per day) and <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (20 mg per day to 1.5 <span class=\"nowrap\">mg/kg</span> per day) have been used for therapy. Between two and several months of treatment is usually required to achieve a satisfactory response. A more rapid response to oral retinoid therapy has been reported in a patient who developed multiple KAs secondary to <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a> therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/58\" class=\"abstract_t\">58</a>].</p><p><br/>Although long-term maintenance therapy may be required [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/45,50,55,57\" class=\"abstract_t\">45,50,55,57</a>], persistent remission after the discontinuation of therapy has been reported in individual patients with MSSE, eruptive keratoacanthomas of Grzybowski, and keratoacanthoma centrifugum marginatum [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/46-48\" class=\"abstract_t\">46-48</a>]. Atrophic scars may remain at the sites of healed lesions.</p><p>Multiple adverse effects are associated with systemic retinoid therapy, including cheilitis, xerosis, visual changes, transaminitis, hyperlipidemia, and teratogenicity. Pregnancy should be avoided for one month after <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy and for three years after the discontinuation of <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>. Thus, treatment with acitretin is usually avoided in women of child-bearing age.</p><p>Other systemic therapies that have been used in a few patients with multiple KAs include <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> plus <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/59\" class=\"abstract_t\">59</a>], <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/60\" class=\"abstract_t\">60</a>], and intravenous 5-FU [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H208437\"><span class=\"h2\">Subungual keratoacanthoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although spontaneous resolution of subungual KA has been reported [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/62,63\" class=\"abstract_t\">62,63</a>], these lesions typically persist [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/5\" class=\"abstract_t\">5</a>]. Surgical excision is the preferred therapeutic intervention. Curettage with or without electrodesiccation and systemic <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> have also been utilized [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. Digital amputation is reserved for lesions that fail to respond to other therapies [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. </p><p class=\"headingAnchor\" id=\"H208445\"><span class=\"h2\">Muir-Torre variant of Lynch syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Muir-Torre variant of Lynch syndrome may present with sebaceous tumors, visceral malignancies, and KA. The management of patients with this syndrome is reviewed separately. (See <a href=\"topic.htm?path=muir-torre-syndrome\" class=\"medical medical_review\">&quot;Muir-Torre syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1564331\"><span class=\"h1\">PROGNOSIS</span></p><p class=\"headingAnchor\" id=\"H287594\"><span class=\"h2\">Recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incomplete removal of KA may result in lesion recurrence. As a group, the rate of recurrence after excision or ED&amp;C is estimated to be between 3 and 8 percent [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/8\" class=\"abstract_t\">8</a>]. </p><p class=\"headingAnchor\" id=\"H1564338\"><span class=\"h2\">Involution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although it is generally well accepted that solitary KAs usually spontaneously regress, detailed documentation of lesions followed through to regression is limited [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/8,65\" class=\"abstract_t\">8,65</a>]. In a retrospective review of 19 patients followed with serial photographs by a single clinician, four out of five patients who had the lesions surgically removed during observation did so due to concern about the clinical behavior of the lesion [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/8\" class=\"abstract_t\">8</a>]. Among the 14 patients followed to lesion involution, the mean time to resolution was 27 weeks. No recurrences were observed during patient follow-up, which ranged from nine months to eight years.</p><p>The type of KA influences the likelihood for spontaneous resolution. Unlike solitary KA and individual lesions in multiple self-healing squamous epithelioma (Ferguson-Smith disease) and generalized eruptive keratoacanthoma of Grzybowski, involution is unlikely to occur in mucosal KA, subungual KA, and keratoacanthoma centrifugum marginatum. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H15906018\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Clinical variants'</a>.)</p><p class=\"headingAnchor\" id=\"H1564345\"><span class=\"h2\">Metastasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although cases of metastatic KA have been reported [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/66-68\" class=\"abstract_t\">66-68</a>], the incidence of this appears to be exceedingly low and there is some question as to whether some or all of the few cases reported as metastatic KA actually represent the misdiagnosis of squamous cell carcinoma [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/1,69,70\" class=\"abstract_t\">1,69,70</a>]. </p><p>The relevance of the histopathologic detection of perineural invasion in 1 to 4 percent of KAs, a finding associated with an increased risk for local recurrence and metastasis in cutaneous squamous cell carcinoma, is uncertain [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/71-73\" class=\"abstract_t\">71-73</a>]. Perineural invasion in KA has generally been considered an incidental finding with little impact on prognosis [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/72,74\" class=\"abstract_t\">72,74</a>]. In the largest series documenting cases of KA with perineural invasion, 1 out of 40 lesions recurred and no metastases were noted [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/71\" class=\"abstract_t\">71</a>]. However, aggressive local behavior of a KA with histopathologic evidence for perineural invasion has also been reported [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H1564574\"><span class=\"h1\">FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients should be instructed to return for reevaluation if signs of lesion regrowth occur after treatment. The appropriate interval for routine clinical follow-up is not standardized. We typically see patients with small, uncomplicated, solitary KAs six months after treatment for reevaluation of the treatment site and a full skin examination. We then follow these patients once yearly. </p><p>Certain clinical scenarios may demand more frequent follow-up. Earlier and more frequent follow-up is appropriate for patients with large, aggressive, or multiple lesions.</p><p class=\"headingAnchor\" id=\"H1564567\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since ultraviolet light exposure likely contributes to the development of KA, daily sun protective measures (application of sunscreen, use of sun-protective clothing, and midday sun avoidance) are recommended as a preventive measure. As noted above, patients with multiple KA syndromes may benefit from long term systemic retinoid therapy to reduce the development of new lesions.</p><p class=\"headingAnchor\" id=\"H1564616\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Keratoacanthoma (KA) is a cutaneous squamoproliferative tumor with the potential for spontaneous resolution (<a href=\"image.htm?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368\" class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \">picture 1A-E</a>). Due to the difficulty in distinguishing KA from cutaneous squamous cell carcinoma, most authors recommend treatment of these lesions. (See <a href=\"#H770530\" class=\"local\">'Overview'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest surgical excision as the first-line treatment for KA (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Surgical excision provides pathologic confirmation of tumor removal. Conventional surgical excision may be performed on most lesions. Lesions in areas where tissue sparing is desired, such as the central face, can be treated with Mohs surgery. (See <a href=\"#H380984\" class=\"local\">'First-line therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other effective options for the treatment of KA include electrodesiccation and curettage (ED&amp;C), intralesional pharmacologic therapy, radiation therapy, and topical therapy. A disadvantage of these interventions compared with surgical excision is the lack of histopathologic confirmation of tumor removal. (See <a href=\"#H770565\" class=\"local\">'Alternative therapies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who elect to defer therapy and prefer to wait for lesion spontaneous resolution, close clinical follow-up should be implemented. Spontaneous resolution may take several months or longer. If lesions deviate from the expected clinical course, surgical excision to confirm the diagnosis is indicated. (See <a href=\"#H770593\" class=\"local\">'Deferring therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The local therapies commonly utilized for the management of solitary KA may be impractical for patients with hundreds or thousands of lesions. For patients with numerous KAs, we suggest treatment with oral retinoid therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/1\" class=\"nounderline abstract_t\">Jackson IT. Diagnostic problem of keratoacanthoma. Lancet 1969; 1:490.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/2\" class=\"nounderline abstract_t\">Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 2007; 46:671.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/3\" class=\"nounderline abstract_t\">Kingman J, Callen JP. Keratoacanthoma. A clinical study. Arch Dermatol 1984; 120:736.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/4\" class=\"nounderline abstract_t\">Browne F, O'Connell M, Merchant W, et al. Spontaneous resolution of a giant keratoacanthoma penetrating through the nose. Clin Exp Dermatol 2011; 36:369.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/5\" class=\"nounderline abstract_t\">Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol 2010; 28:254.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/6\" class=\"nounderline abstract_t\">Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004; 30:326.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/7\" class=\"nounderline abstract_t\">Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994; 30:1.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/8\" class=\"nounderline abstract_t\">Griffiths RW. Keratoacanthoma observed. Br J Plast Surg 2004; 57:485.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/9\" class=\"nounderline abstract_t\">Tran DC, Li S, Henry AS, et al. An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic center. Br J Dermatol 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/10\" class=\"nounderline abstract_t\">Garcia-Zuazaga J, Ke M, Lee P. Giant keratoacanthoma of the upper extremity treated with mohs micrographic surgery: a case report and review of current treatment modalities. J Clin Aesthet Dermatol 2009; 2:22.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/11\" class=\"nounderline abstract_t\">Shriner DL, McCoy DK, Goldberg DJ, Wagner RF Jr. Mohs micrographic surgery. J Am Acad Dermatol 1998; 39:79.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/12\" class=\"nounderline abstract_t\">Nedwich JA. Evaluation of curettage and electrodesiccation in treatment of keratoacanthoma. Australas J Dermatol 1991; 32:137.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/13\" class=\"nounderline abstract_t\">Cohen PR, Schulze KE, Teller CF, Nelson BR. Intralesional methotrexate for keratoacanthoma of the nose. Skinmed 2005; 4:393.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/14\" class=\"nounderline abstract_t\">Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007; 56:989.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/15\" class=\"nounderline abstract_t\">Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol 1991; 25:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/16\" class=\"nounderline abstract_t\">Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol 2010; 63:689.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/17\" class=\"nounderline abstract_t\">Goette DK, Odom RB. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol 1980; 2:212.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/18\" class=\"nounderline abstract_t\">Martorell-Calatayud A, Requena C, Nagore E, et al. [Intralesional infusion of methotrexate as neoadjuvant therapy improves the cosmetic and functional results of surgery to treat keratoacanthoma: results of a randomized trial]. Actas Dermosifiliogr 2011; 102:605.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/19\" class=\"nounderline abstract_t\">Andreassi A, Pianigiani E, Taddeucci P, et al. Guess what! Keratoacanthoma treated with intralesional bleomycin. Eur J Dermatol 1999; 9:403.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/20\" class=\"nounderline abstract_t\">Sayama S, Tagami H. Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol 1983; 109:449.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/21\" class=\"nounderline abstract_t\">de la Torre C, Losada A, Cruces MJ. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol 1997; 37:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/22\" class=\"nounderline abstract_t\">Rapaport J. Giant keratoacanthoma of the nose. Arch Dermatol 1975; 111:73.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/23\" class=\"nounderline abstract_t\">Oh CK, Son HS, Lee JB, et al. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol 2004; 51:S177.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/24\" class=\"nounderline abstract_t\">Grob JJ, Suzini F, Richard MA, et al. Large keratoacanthomas treated with intralesional interferon alfa-2a. J Am Acad Dermatol 1993; 29:237.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/25\" class=\"nounderline abstract_t\">Goebeler M, Lurz C, Kolve-Goebeler ME, Br&ouml;cker EB. Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration. Arch Dermatol 2001; 137:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/26\" class=\"nounderline abstract_t\">Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol 2005; 4:648.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/27\" class=\"nounderline abstract_t\">Caccialanza M, Sopelana N. Radiation therapy of keratoacanthomas: results in 55 patients. Int J Radiat Oncol Biol Phys 1989; 16:475.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/28\" class=\"nounderline abstract_t\">Donahue B, Cooper JS, Rush S. Treatment of aggressive keratoacanthomas by radiotherapy. J Am Acad Dermatol 1990; 23:489.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/29\" class=\"nounderline abstract_t\">Shimm DS, Duttenhaver JR, Doucette J, Wang CC. Radiation therapy of keratoacanthoma. Int J Radiat Oncol Biol Phys 1983; 9:759.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/30\" class=\"nounderline abstract_t\">Basoglu Y, Metze D, Nashan D, St&auml;nder S. Keratoacanthoma with perineural invasion: an indicator for aggressive behavior? J Dtsch Dermatol Ges 2008; 6:952.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/31\" class=\"nounderline abstract_t\">Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol 1993; 129:1162.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/32\" class=\"nounderline abstract_t\">Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self-healing squamous epithelioma (Ferguson-Smith disease) with radiotherapy, which was successfully treated with acitretin. Clin Exp Dermatol 2010; 35:e100.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/33\" class=\"nounderline abstract_t\">Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat 2009; 20:328.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/34\" class=\"nounderline abstract_t\">Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg 2000; 44:82.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/35\" class=\"nounderline abstract_t\">Ebner H, Mischer P. [The local treatment of the keratoacanthoma with 5-fluorouracil]. Hautarzt 1975; 26:585.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/36\" class=\"nounderline abstract_t\">Jeon HC, Choi M, Paik SH, et al. Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report. Ann Dermatol 2011; 23:357.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/37\" class=\"nounderline abstract_t\">Neumann RA, Knobler RM. Argon laser treatment of small keratoacanthomas in difficult locations. Int J Dermatol 1990; 29:733.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/38\" class=\"nounderline abstract_t\">Thiele JJ, Ziemer M, Fuchs S, Elsner P. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg 2004; 30:1556.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/39\" class=\"nounderline abstract_t\">Alloo A, Garibyan L, LeBoeuf N, et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012; 148:363.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/40\" class=\"nounderline abstract_t\">Mamelak AJ, Goldberg LH, Marquez D, et al. Eruptive keratoacanthomas on the legs after fractional photothermolysis: report of two cases. Dermatol Surg 2009; 35:513.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/41\" class=\"nounderline abstract_t\">Gewirtzman A, Meirson DH, Rabinovitz H. Eruptive keratoacanthomas following carbon dioxide laser resurfacing. Dermatol Surg 1999; 25:666.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/42\" class=\"nounderline abstract_t\">Bunker CB. Keratoacanthoma, trauma, and cryotherapy. Dermatol Surg 2011; 37:1709.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/43\" class=\"nounderline abstract_t\">Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol 2006; 20:197.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/44\" class=\"nounderline abstract_t\">Yeon JH, Jung JY, Choi JW, et al. Keratoacanthoma aggravated after photodynamic therapy. J Dermatol 2010; 37:765.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/45\" class=\"nounderline abstract_t\">Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol 2007; 46:77.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/46\" class=\"nounderline abstract_t\">Vandergriff T, Nakamura K, High WA. Generalized eruptive keratoacanthomas of Grzybowski treated with isotretinoin. J Drugs Dermatol 2008; 7:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/47\" class=\"nounderline abstract_t\">Aydin F, Senturk N, Sabanciler E, et al. A case of Ferguson-Smith type multiple keratoacanthomas associated with keratoacanthoma centrifugum marginatum: response to oral acitretin. Clin Exp Dermatol 2007; 32:683.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/48\" class=\"nounderline abstract_t\">Kato N, Ito K, Kimura K, Shibata M. Ferguson Smith type multiple keratoacanthomas and a keratoacanthoma centrifugum marginatum in a woman from Japan. J Am Acad Dermatol 2003; 49:741.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/49\" class=\"nounderline abstract_t\">Benoldi D, Alinovi A. Multiple persistent keratoacanthomas: treatment with oral etretinate. J Am Acad Dermatol 1984; 10:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/50\" class=\"nounderline abstract_t\">Haydey RP, Reed ML, Dzubow LM, Shupack JL. Treatment of keratoacanthomas with oral 13-cis-retinoic acid. N Engl J Med 1980; 303:560.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/51\" class=\"nounderline abstract_t\">Ogasawara Y, Kinoshita E, Ishida T, et al. A case of multiple keratoacanthoma centrifugum marginatum: response to oral etretinate. J Am Acad Dermatol 2003; 48:282.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/52\" class=\"nounderline abstract_t\">Blitstein-Willinger E, Haas N, N&uuml;rnberger F, St&uuml;ttgen G. Immunological findings during treatment of multiple keratoacanthoma with etretinate. Br J Dermatol 1986; 114:109.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/53\" class=\"nounderline abstract_t\">Barysch MJ, Kamarashev J, Lockwood LL, Dummer R. Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin. J Dermatol 2011; 38:390.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/54\" class=\"nounderline abstract_t\">Cherif F, Mebazaa A, Kort R, et al. [Multiple keratoacanthoma centrifugum marginatum]. Ann Dermatol Venereol 2002; 129:413.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/55\" class=\"nounderline abstract_t\">Schaller M, Korting HC, Wolff H, et al. Multiple keratoacanthomas, giant keratoacanthoma and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Derm Venereol 1996; 76:40.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/56\" class=\"nounderline abstract_t\">Shaw JC, Storrs FJ, Everts E. Multiple keratoacanthomas after megavoltage radiation therapy. J Am Acad Dermatol 1990; 23:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/57\" class=\"nounderline abstract_t\">Shaw JC, White CR Jr. Treatment of multiple keratoacanthomas with oral isotretinoin. J Am Acad Dermatol 1986; 15:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/58\" class=\"nounderline abstract_t\">Sachse MM, Wagner G. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids. Br J Dermatol 2014; 170:475.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/59\" class=\"nounderline abstract_t\">Mangas C, Bielsa I, Ribera M, et al. A case of multiple keratoacanthoma centrifugum marginatum. Dermatol Surg 2004; 30:803.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/60\" class=\"nounderline abstract_t\">Oakley A, Ng S. Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide. Australas J Dermatol 2005; 46:118.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/61\" class=\"nounderline abstract_t\">Agarwal M, Chander R, Karmakar S, Walia R. Multiple familial keratoacanthoma of Witten and Zak - A report of three siblings. Dermatology 1999; 198:396.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/62\" class=\"nounderline abstract_t\">Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual keratoacanthoma with reossification of underlying distal lytic phalynx. Clin Exp Dermatol 2005; 30:20.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/63\" class=\"nounderline abstract_t\">Oliwiecki S, Peachey RD, Bradfield JW, et al. Subungual keratoacanthoma--a report of four cases and review of the literature. Clin Exp Dermatol 1994; 19:230.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/64\" class=\"nounderline abstract_t\">Baran R, Goettmann S. Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Br J Dermatol 1998; 139:512.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/65\" class=\"nounderline abstract_t\">Ko CJ, McNiff JM, Bosenberg M, Choate KA. Keratoacanthoma: clinical and histopathologic features of regression. J Am Acad Dermatol 2012; 67:1008.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/66\" class=\"nounderline abstract_t\">Ansai S, Manabe M. Possible spontaneous regression of a metastatic lesion of keratoacanthoma-like squamous cell carcinoma in a regional lymph node. J Dermatol 2005; 32:899.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/67\" class=\"nounderline abstract_t\">Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993; 15:332.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/68\" class=\"nounderline abstract_t\">Davis BA, Monheit GD, Kline L. Metastatic skin cancer presenting as ptosis and diplopia. Dermatol Surg 2006; 32:148.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/69\" class=\"nounderline abstract_t\">Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009; 26:150.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/70\" class=\"nounderline abstract_t\">Schnur PL, Bozzo P. Metastasizing keratoacanthomas? The difficulties in differentiating keratoacanthomas from squamous cell carcinomas. Plast Reconstr Surg 1978; 62:258.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/71\" class=\"nounderline abstract_t\">Godbolt AM, Sullivan JJ, Weedon D. Keratoacanthoma with perineural invasion: a report of 40 cases. Australas J Dermatol 2001; 42:168.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/72\" class=\"nounderline abstract_t\">Petrie M, Eliezri Y, Campanelli C. Keratoacanthoma of the head and neck with perineural invasion: incidental finding or cause for concern? Dermatol Surg 2010; 36:1209.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-management-and-prognosis/abstract/73\" class=\"nounderline abstract_t\">Cooper PH, Wolfe JT 3rd. Perioral keratoacanthomas with extensive perineural invasion and intravenous growth. Arch Dermatol 1988; 124:1397.</a></li><li class=\"breakAll\">Weedon D. Tumors of the epidermis. In: Weedon's Skin Pathology, 3rd Ed, Elsevier Limited, 2010. p.667.</li></ol></div><div id=\"topicVersionRevision\">Topic 17112 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1564616\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H771357\" id=\"outline-link-H771357\">INTRODUCTION</a></li><li><a href=\"#H770530\" id=\"outline-link-H770530\">OVERVIEW</a></li><li><a href=\"#H770537\" id=\"outline-link-H770537\">SOLITARY KERATOACANTHOMA</a><ul><li><a href=\"#H380984\" id=\"outline-link-H380984\">First-line therapy</a><ul><li><a href=\"#H770544\" id=\"outline-link-H770544\">- Conventional surgical excision</a></li><li><a href=\"#H770551\" id=\"outline-link-H770551\">- Mohs surgery</a></li></ul></li><li><a href=\"#H770565\" id=\"outline-link-H770565\">Alternative therapies</a><ul><li><a href=\"#H380965\" id=\"outline-link-H380965\">- Electrodesiccation and curettage</a></li><li><a href=\"#H770579\" id=\"outline-link-H770579\">- Intralesional therapy</a></li><li><a href=\"#H1564847\" id=\"outline-link-H1564847\">- Radiation</a></li><li><a href=\"#H210572\" id=\"outline-link-H210572\">- Topical therapy</a></li><li><a href=\"#H770586\" id=\"outline-link-H770586\">- Other</a></li></ul></li><li><a href=\"#H770593\" id=\"outline-link-H770593\">Deferring therapy</a></li></ul></li><li><a href=\"#H770600\" id=\"outline-link-H770600\">SPECIAL CASES</a><ul><li><a href=\"#H207224\" id=\"outline-link-H207224\">Multiple and large keratoacanthomas</a></li><li><a href=\"#H208437\" id=\"outline-link-H208437\">Subungual keratoacanthoma</a></li><li><a href=\"#H208445\" id=\"outline-link-H208445\">Muir-Torre variant of Lynch syndrome</a></li></ul></li><li><a href=\"#H1564331\" id=\"outline-link-H1564331\">PROGNOSIS</a><ul><li><a href=\"#H287594\" id=\"outline-link-H287594\">Recurrence</a></li><li><a href=\"#H1564338\" id=\"outline-link-H1564338\">Involution</a></li><li><a href=\"#H1564345\" id=\"outline-link-H1564345\">Metastasis</a></li></ul></li><li><a href=\"#H1564574\" id=\"outline-link-H1564574\">FOLLOW-UP</a></li><li><a href=\"#H1564567\" id=\"outline-link-H1564567\">PREVENTION</a></li><li><a href=\"#H1564616\" id=\"outline-link-H1564616\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/17112|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/55042\" class=\"graphic graphic_picture\">- Keratoacanthoma - face</a></li><li><a href=\"image.htm?imageKey=DERM/81629\" class=\"graphic graphic_picture\">- Keratoacanthoma on ear</a></li><li><a href=\"image.htm?imageKey=DERM/59593\" class=\"graphic graphic_picture\">- Keratoacanthoma on hand</a></li><li><a href=\"image.htm?imageKey=DERM/73408\" class=\"graphic graphic_picture\">- Solitary keratoacanthoma</a></li><li><a href=\"image.htm?imageKey=DERM/52368\" class=\"graphic graphic_picture\">- Keratoacanthoma on eyelid</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis\" class=\"medical medical_review\">Keratoacanthoma: Epidemiology, risk factors, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mohs-surgery\" class=\"medical medical_review\">Mohs surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=muir-torre-syndrome\" class=\"medical medical_review\">Muir-Torre syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">Treatment and prognosis of cutaneous squamous cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-basal-cell-carcinomas-at-high-risk-for-recurrence\" class=\"medical medical_review\">Treatment of basal cell carcinomas at high risk for recurrence</a></li></ul></div></div>","javascript":null}